Your browser doesn't support javascript.
A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities.
Dhooria, Sahajal; Maturu, Venkata Nagarjuna; Talwar, Deepak; Kumar, Sachin; Handa, Ajay; Agrawal, Priya Nath; Jindal, Aditya; Tampi, P S; Goyal, Abhishek; Maskey, Dipesh; Aggarwal, Ashutosh Nath; Behera, Digambar; Jindal, Surinder Kumar.
  • Dhooria S; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Maturu VN; Department of Pulmonary Medicine, Yashoda Hospitals, Hyderabad, Telangana, India.
  • Talwar D; Metro Centre for Respiratory Diseases, Noida, Uttar Pradesh, India.
  • Kumar S; Department of Pulmonary Medicine, Sakra World Hospital, Bengaluru, Karnataka, India.
  • Handa A; Department of Pulmonary Medicine, Sakra World Hospital, Bengaluru, Karnataka, India.
  • Agrawal PN; Department of Pulmonary Medicine, Agrawal Hospital, Bhopal, Madhya Pradesh, India.
  • Jindal A; Jindal Clinics, Chandigarh, India.
  • Tampi PS; Bombay Hospital and Medical Research Center, Mumbai, Maharashtra, India.
  • Goyal A; Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
  • Maskey D; Department of Pulmonary Medicine, MMI Narayana Multispeciality Hospital, Raipur, Chhattisgarh, India.
  • Aggarwal AN; Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Behera D; Department of Pulmonary Medicine, Fortis Hospital, Chandigarh, India.
  • Jindal SK; Jindal Clinics, Chandigarh, India.
Lung India ; 39(3): 254-260, 2022.
Article in English | MEDLINE | ID: covidwho-1810864
ABSTRACT

Background:

Little data exist on antifibrotic drugs for treating symptomatic patients with persistent interstitial lung abnormalities in the postacute phase of coronavirus disease 2019 (COVID-19). Herein, we describe the physician practices of prescribing pirfenidone and nintedanib for these patients and the physician-assessed response. Materials and

Methods:

This was a multicenter, retrospective survey study of subjects administered pirfenidone or nintedanib for post-COVID-19 interstitial lung abnormalities. Data on the demographic details, comorbidities, abnormalities on the computed tomography (CT) of the chest, treatment, antifibrotic drug use, and physician-assessed response were collected on a standard case record pro forma. We explored physician practices of prescribing antifibrotics (primary objective) and the physician-assessed response (secondary objective).

Results:

We included 142 subjects (mean age, 55.9 years; 16.2% women) at eight centers. The most common abnormalities on CT chest included ground glass opacities (75.7%), consolidation (49.5%), reticulation (43.9%), and parenchymal bands (16.8%). Of the 5701 patients discharged after hospitalization at six centers, 115 (2.0%) received antifibrotics. The drugs were prescribed an average of 26 days after symptom onset. One hundred and sixteen subjects were administered pirfenidone; 11 (9.5%) received the full dose (2400 mg/day). Thirty subjects were prescribed nintedanib; 23 (76.7%) received the full dose (300 mg/day). Of 76 subjects with available information, 27 (35.6%) and 26 (34.2%) had significant or partial radiologic improvement, respectively, according to the physician's assessment.

Conclusions:

Antifibrotic agents were administered to a minority of patients discharged after recovery from acute COVID-19 pneumonia. Larger, randomized studies on the efficacy and safety of these agents are required.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Long Covid Language: English Journal: Lung India Year: 2022 Document Type: Article Affiliation country: Lungindia.lungindia_568_21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Long Covid Language: English Journal: Lung India Year: 2022 Document Type: Article Affiliation country: Lungindia.lungindia_568_21